The insider trading reports reveal that during the month of June, Sopharma sold 8 883 500 own shares (91.8% of the traded volume during the month) at an average price of EUR 1.90 per share. Total treasury stock after the transactions stood at 752 500 or 0.14% of issued shares. For the first half of the year, Sopharma sold 12 872 041 own shares (77.9% of the traded volume during the period) at an average price of EUR 1.87 per share. Ognyan Donev, who is an Executive Director, Chairman of the BoD and largest beneficiary owner of Sopharma, has net purchases of 1 200 Sopharma’s shares directly and net purchases of 16 150 shares through one of his companies. Our calculations show that as of the end of June, Ognyan Donev is 0.0009% shy of 50% stake.